Angion stock falls after agreeing Elicio Therapeutics merger
pharmaphorum
JANUARY 17, 2023
Angion chalked up a series of trial failures for its hepatocyte growth factor (HGF) mimetic ANG-3777 over the last couple of years, and turned its attention to tyrosine kinase receptor inhibitor ANG-3070 in kidney diseases and fibrotic disorders, before abandoning the drug due to safety concerns in the middle of 2022. Darrell Irvine.
62 
Let's personalize your content